FDA Approves Eltrombopag Olamine Application by Biocon Pharma
The FDA has approved the application ANDA220660 for Eltrombopag Olamine submitted by Biocon Pharma.
Therapeutic Area
Therapeutic area intelligence for Thrombocytopenia with 5 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
A clinical trial is investigating the effectiveness of C1q-binding HLA antibodies in predicting platelet transfusion responses in thrombocytopenic patients.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.